Antioxidant Supplement for Blood Vessel Health
Trial Summary
Will I have to stop taking my current medications?
Yes, you may need to stop taking certain medications. The trial excludes participants who are taking medications that could affect cardiovascular responses or specific drugs like chloramphenicol, cholestyramine, and others listed.
What data supports the effectiveness of the drug MitoQ for blood vessel health?
Research shows that MitoQ, a mitochondrial-targeted antioxidant, improves blood vessel function in older adults by reducing oxidative stress and improving the flexibility of arteries. In studies, MitoQ increased blood flow and reduced arterial stiffness, suggesting it may help with age-related blood vessel issues.12345
Is MitoQ safe for human use?
MitoQ, a mitochondria-targeted antioxidant, has been tested in clinical trials with healthy older adults and was well tolerated, showing no significant safety concerns. It has been used in studies to improve vascular function and reduce oxidative stress, suggesting it is generally safe for human use.13467
How is the drug MitoQ different from other treatments for blood vessel health?
MitoQ is unique because it specifically targets mitochondria (the energy-producing parts of cells) to reduce oxidative stress, which is a key factor in age-related blood vessel problems. Unlike other antioxidants, MitoQ is designed to improve blood vessel function by directly reducing harmful substances in the mitochondria, potentially offering a more effective approach for older adults.12689
What is the purpose of this trial?
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide, and the non-Hispanic Black (NHB) population is disproportionately affected. Our research has previously demonstrated that oxidative stress may contribute to reduced vascular function in otherwise healthy NHB adults, potentially predisposing them to the development of hypertension and CVD. This study is designed to examine whether the mitochondria are an important source of oxidative stress-induced vascular dysfunction in healthy NHB adults.
Eligibility Criteria
This trial is for healthy non-Hispanic Black or White adults, aged 18-60, with normal blood pressure and cholesterol levels. Participants should not have diabetes (HbA1C <6.0%). It's designed to study blood vessel health in those who are not currently diagnosed with hypertension or cardiovascular disease.Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single dose of 80mg MitoQ or placebo, followed by a crossover to the other treatment after a minimum of 14 days
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- MitoQ
Find a Clinic Near You
Who Is Running the Clinical Trial?
S. Tony Wolf
Lead Sponsor
University of Georgia
Lead Sponsor